Are Meningiomas Genetic? Explaining the Inherited Risk

Most meningiomas are not inherited in the traditional sense of being passed directly from parent to child through a single gene. The vast majority arise from random genetic changes that occur in the cells of the meninges over a person’s lifetime. But genetics still matter: people with a first-degree relative who had a meningioma face roughly four times the usual risk, and a handful of inherited syndromes dramatically raise the odds. The relationship between meningiomas and genetics is more layered than a simple yes-or-no, involving inherited predisposition syndromes, acquired mutations within tumors, and common gene variants that nudge risk up modestly across the population.

Family History and How Much It Raises Risk

Even when known genetic syndromes are excluded from the analysis, having a close relative with a meningioma meaningfully increases your own risk. A case-control study that specifically removed individuals with neurofibromatosis type 2 (the best-known meningioma predisposition syndrome) still found that patients with meningiomas were about four and a half times more likely than controls to report a first-degree family member with an intracranial meningioma.¹ A separate analysis found a similar elevation in risk among people who reported a family history of any benign brain tumor.²

Those numbers sound alarming, but context helps. Meningiomas are the most common primary brain tumor, yet they are still uncommon in absolute terms. A fourfold increase in a small baseline risk remains a small number for any individual. What the family-history data tell us is that there is a heritable component to meningioma susceptibility that goes beyond the rare syndromes geneticists already know about. The genes responsible for this “background” familial risk are not yet fully identified, which makes the finding both meaningful and frustrating: it points toward inherited vulnerability without yet giving people a specific gene to test for.

Neurofibromatosis Type 2, the Biggest Single-Gene Risk Factor

The strongest known genetic link to meningiomas comes from neurofibromatosis type 2, a condition caused by mutations in the NF2 gene. That gene produces a tumor-suppressor protein called merlin, which normally keeps cells from growing unchecked. When both copies of NF2 are disabled, the brake is released. People with NF2 carry a germline mutation in one copy of the gene from birth, so every cell in their body starts halfway to losing that brake.³

Roughly half of people diagnosed with NF2 develop at least one meningioma over their lifetime, and NF2 loss-of-function turns up in up to 60% of sporadic meningiomas as well, meaning the gene is relevant far beyond the inherited syndrome.⁴ The difference is that in sporadic cases, both copies of NF2 are knocked out by chance mutations acquired during life, rather than one being inherited. NF2-related meningiomas also tend to appear at younger ages and are more likely to be multiple, which is one reason clinicians pay close attention when a young person shows up with a meningioma or more than one at the same time.

Other Inherited Syndromes That Include Meningioma

NF2 gets the most attention, but it is not the only inherited condition that raises meningioma risk. Several other cancer predisposition syndromes have meningioma in their roster of associated tumors.

• BAP1 tumor predisposition syndrome: Germline mutations in the BAP1 gene predispose people to uveal melanoma, mesothelioma, lung cancer, and meningioma. Families carrying these mutations can develop multiple primary cancers across different organs, including meningiomas alongside other tumor types.⁵ In one documented family, two out of five members who developed mesothelioma also had meningiomas, all sharing the same BAP1 mutation.⁶
• Cowden syndrome (PTEN hamartoma tumor syndrome): Caused by germline PTEN mutations, Cowden syndrome leads to benign growths throughout the body plus elevated risk of breast, thyroid, and other cancers. A systematic review found meningiomas in about 8% of Cowden syndrome patients, a rate far higher than the general population.⁷
• Additional syndromes: Gorlin syndrome (also called nevoid basal cell carcinoma syndrome), Werner syndrome, and rhabdoid tumor predisposition syndrome have all been linked to meningiomas, particularly in children and adolescents. In younger patients, meningiomas and schwannomas are frequently tied to an underlying cancer predisposition syndrome.⁸

The practical lesson from these syndromes is that a meningioma appearing alongside other unusual tumors, or appearing in a young person, should prompt a conversation about genetic evaluation. Most people with a single meningioma diagnosed in middle age do not have one of these syndromes, but the possibility is worth ruling out when the clinical picture is atypical.

What Young Patients Should Know About Genetic Workup

When a child, teenager, or young adult is diagnosed with a solitary meningioma or schwannoma, guidelines recommend a thorough search for additional tumors before assuming it is just a one-off event. That workup typically includes full craniospinal MRI with thin imaging slices through the internal auditory canals, along with a dermatologic exam for skin plaques associated with NF2 and an eye exam looking for lens opacities or retinal abnormalities.⁹ The rationale is simple: in younger patients the probability that the tumor signals an underlying genetic syndrome is substantially higher than in someone diagnosed at age 60.

Pediatric meningiomas also look different under the molecular microscope. Compared with adult tumors, they cluster separately in molecular profiling and frequently carry NF2 alterations, while the other mutations commonly found in adult non-NF2 tumors are largely absent.¹⁰ This suggests that the biological pathways driving meningiomas in children are not the same mix of pathways active in adults, which has implications for how aggressively these tumors are monitored and what treatments might eventually be targeted at them.

Sporadic Mutations Inside the Tumor

For the majority of meningioma patients who do not have a hereditary syndrome, the genetic changes that matter are somatic: they arise within the tumor cells themselves, not in the person’s inherited DNA. A landmark genomic analysis of 300 meningiomas revealed that roughly a quarter carry mutations in TRAF7, an enzyme involved in cell death signaling. Those TRAF7 mutations frequently co-occurred with a specific change in KLF4 or with the well-known AKT1 E17K mutation, which activates a cell-growth pathway. About 5% of non-NF2 meningiomas carried mutations in SMO, which activates a different growth signal.¹¹

These somatic mutations split meningiomas into two broad camps. Tumors with NF2 loss show up in both low-grade and high-grade forms and are scattered throughout the skull. Tumors without NF2 loss tend to carry those TRAF7, KLF4, AKT1, or SMO mutations instead and are more frequently benign.¹² None of these somatic mutations are something you inherit or can test for in a blood sample before the tumor appears; they matter for prognosis and treatment decisions after a meningioma has already been found.

Where the Tumor Sits Can Reflect Its Genetic Profile

One of the more surprising findings in meningioma research is that the physical location of a tumor inside the skull is linked to its underlying genetics. Meningiomas growing along the front midline of the skull base and in the area behind the brain tend to carry low-risk molecular profiles and are predominantly low-grade. Tumors on the brain’s convexity (the outer surface of the cerebral hemispheres) or within the ventricles are more often enriched for high-grade genetic features, including heavier loads of chromosomal copy-number changes.¹³

This location-genetics connection is relevant because it means two meningiomas of the same size and apparent grade under the microscope can behave very differently depending on where they sit and what mutations are driving them. It is one reason the field has been moving toward molecular classification rather than relying solely on how the tumor looks under a traditional microscope.

High-Grade Meningiomas and Their Molecular Markers

Most meningiomas are benign (WHO grade 1). A smaller fraction are atypical (grade 2), and a still smaller group are anaplastic or malignant (grade 3). The 2021 World Health Organization guidelines changed how grade 3 meningiomas are defined by incorporating molecular markers for the first time. Now, a meningioma can be classified as grade 3 based on either its microscopic appearance or the presence of specific genetic changes: homozygous deletion of the CDKN2A/B genes or mutations in the TERT promoter.¹⁴ These are somatic changes within the tumor, not inherited ones, but they carry serious weight in predicting how aggressively a meningioma will behave.

Molecular classification goes further than just grading. An integrated approach combining copy-number variation data and DNA methylation profiling with traditional morphology predicts the risk of tumor recurrence significantly better than the WHO grading system alone.¹⁵ DNA methylation profiling, in particular, has identified three distinct meningioma groups with different clinical outcomes, biological drivers, and potential drug targets.¹⁶ This kind of profiling does not tell you whether your meningioma was inherited, but it tells your surgeon and oncologist a great deal about how it is likely to act.

Common Gene Variants and Population-Wide Risk

Beyond the rare syndromes, researchers have been using genome-wide association studies to look for common genetic variants that slightly increase meningioma risk across the general population. A European-ancestry study identified a susceptibility locus on chromosome 11p15.5, near a gene called RIC8A that is involved in the development of meninges-like structures. People carrying the risk variant had about 44% higher odds of developing a meningioma.¹⁷

A Japanese genome-wide study found suggestive associations but no variants reaching the strictest statistical threshold, with the strongest signal on chromosome 15q25 near the SEC11A gene.¹⁸ The different results across populations highlight that the common genetic architecture of meningioma risk likely varies by ancestry. These common variants individually nudge risk only modestly. They are not the kind of thing that would warrant genetic testing in an individual, but taken together they may eventually help explain why meningiomas cluster in certain families even without a single culpable gene.

Racial and Ethnic Differences in Incidence

Meningioma rates are not uniform across racial and ethnic groups, and at least some of that variation appears to have a genetic component. In the United States, non-Hispanic Black individuals have a roughly 23% higher rate of grade 1 meningiomas and about 42% higher rate of grade 2 and 3 meningiomas compared with non-Hispanic White individuals.¹⁹ These differences likely reflect a mix of genetic, hormonal, and environmental factors rather than any single cause.

A recent prospective genomic profiling study found that the distribution of molecular alterations within meningiomas also varies by demographic group. Asian males in the study showed enrichment for high-risk molecular features, while molecularly favorable tumors were more common in females overall and low-grade tumors were more common in Hispanic individuals.²⁰ These patterns were previously unrecognized because most large meningioma genomic studies had been conducted in predominantly White European populations. As datasets diversify, the picture of who is genetically vulnerable and to which subtypes will continue to sharpen.

How Radiation Exposure Rewires the Genetic Story

Radiation-induced meningiomas are an interesting genetic counterpoint to the sporadic form. People who received radiation to the head, often as children being treated for other conditions, develop meningiomas at elevated rates. But the genetic profile of these tumors differs from sporadic meningiomas in telling ways. Sporadic meningiomas frequently carry NF2 mutations; radiation-induced meningiomas often do not. One analysis found NF2 mutations in half of sporadic tumor samples but in none of the radiation-induced specimens examined.²¹ Instead, radiation-induced tumors more commonly show losses on chromosome 1p and other regions.²²

The finding matters because it suggests that radiation does not simply accelerate the normal process of meningioma formation. It appears to cause a distinct set of genetic damage that leads to tumors through a partly different molecular route. There is also evidence that susceptibility to radiation-induced meningioma runs in families. Among a cohort of people who had received therapeutic radiation, 17 families had two or more members who developed meningiomas, translating to a sibling risk roughly 20-fold above normal. Because the radiation doses were similar across the cohort, the clustering points toward inherited low-penetrance genes that make certain people’s meningeal cells more vulnerable to radiation damage.²³

When Hormones and Genetics Intersect

Meningiomas are about twice as common in women as in men, and they express hormone receptors, which has long suggested a hormonal influence on their growth. The genetic angle on this got sharper when researchers compared meningiomas in women who had been exposed to certain progestin medications (like cyproterone acetate) with meningiomas in women who had not. The progestin-associated tumors had a strikingly different mutational profile: they were far more likely to carry PIK3CA mutations (about 35% compared to 3% in the control group) and TRAF7 mutations, while NF2-related tumors were much less common.²⁴ These progestin-associated tumors were also far more often multiple and more frequently located at the skull base.

This is a vivid example of gene-environment interaction: the hormonal exposure did not create mutations out of thin air, but it apparently favored the growth of cells that happened to carry certain mutations over others. The vulnerability of specific meningeal cell populations to hormone-driven growth depends on which mutations those cells already carry. In some cases, discontinuing the medication led to tumor regression, but not uniformly, and growing tumors that persisted after stopping treatment have shown different mutation patterns from those that shrank.²⁵

Non-Syndromic Familial Multiple Meningiomas

Some families have multiple members who develop meningiomas without carrying NF2 mutations or any other recognized syndrome. This condition, called familial multiple meningioma, is genetically distinct from both NF2-associated and sporadic multiple meningiomas. Genomic profiling shows that these familial cases have their own pattern of chromosomal changes, different from both sporadic tumors and NF2-linked tumors.²⁶ The responsible gene or genes have not yet been identified, which means there is currently no clinical test to offer these families. They represent one of the clearest examples of an inherited meningioma risk that the science has not yet caught up to.

Liquid Biopsy and the Future of Monitoring

For people with a known genetic predisposition, the question of how to monitor for meningiomas without repeated MRI scans is an active area of research. Liquid biopsy, which looks for tumor-derived DNA circulating in the bloodstream, has been explored as a less invasive option. In one study of 27 meningioma patients, researchers found that while tumor tissue itself carried mutations in NF2, PIK3CA, BRAF, and SMO at high rates, only a single matched mutation (in NF2) was detected in paired blood plasma samples.²⁷ Meningiomas, being enclosed by the blood-brain barrier and often slow-growing, shed very little DNA into the bloodstream. Liquid biopsy is not yet ready to replace imaging for meningioma detection, though researchers are also exploring other blood-based markers like microRNAs and cytokines that might eventually prove more sensitive.

Targeted Therapies Emerging From Genetic Discoveries

Understanding which somatic mutations drive a meningioma has opened the door to treatments that go beyond surgery and radiation. AKT1 mutations, found almost exclusively in non-NF2 meningiomas, are especially attractive targets because AKT inhibitors already exist and are being tested in clinical trials. SMO mutations, present in roughly 6% of non-NF2 tumors and concentrated in skull-base meningiomas, are being targeted with SMO inhibitors that were originally developed for other cancers. The broader idea is that screening a tumor’s genetic profile before deciding on adjuvant therapy could improve both treatment selection and clinical trial enrollment.²⁸

These targeted approaches are still mostly in early clinical trials, and the standard of care for most meningiomas remains surgical removal with or without radiation. But for patients with recurrent or inoperable tumors, knowing the molecular profile could mean the difference between a generic drug regimen and a trial that matches the specific biology of their tumor. For inherited cases, where the germline mutation is known, research into how that mutation interacts with these somatic drivers could eventually inform prevention strategies as well.